

## Irritable Bowel Syndrome: A Systemic Review

Dhruvi Mayank Patel\*<sup>1</sup> and Praveen N M<sup>2</sup>

<sup>1</sup>Department of Medical Laboratory Technology, DPG College, Gurgaon-122001

<sup>2</sup>Analytical & Development Department, Stelis Biopharma Pvt. Ltd., Bangalore, Karnataka-560105

### Abstract

Irritable bowel syndromes (IBS) are bio-psychosocial mess arises with abdominal pain and evidence of changing in pattern of bowel movement that impacts the healthcare worldwide. They connect with the brain-gut axis along with the correlation of neuroendocrine system, dejection, and anxiety, the low consumption of carbohydrate which is fermentable oligo-di-mono-saccharides and polyols (FODMAP) may respite throughout bowel syndrome. Correspondingly dietary fibers, anticholinergic drugs therapy may constructive in reducing the complication of bowels syndrome. The review concludes that contemplate supply of microbiota can heal bowel syndrome with unaffected proper diet.

**Keywords:** Irritable bowel syndrome, NES, probiotics, genetic, (fermentable oligosaccharide, disaccharide, monosaccharide, polyols), inflammation.

#### \*Correspondence Info:

Dhruvi Mayank Patel  
Department of Medical Laboratory Technology,  
DPG College, Gurgaon-122001

#### \*Article History:

**Received:** 05/05/2019  
**Revised:** 26/05/2019  
**Accepted:** 27/05/2019  
**DOI:** <https://doi.org/10.7439/ijasr.v5i5.5180>

#### QR Code



**How to cite:** Patel D. M and Praveen N M. Irritable Bowel Syndrome: A Systemic Review. *International Journal of Advances in Scientific Research* 2019; 5(5): e5180. Doi: 10.7439/ijasr.v5i5.5180

Available from: <https://ssjournals.com/index.php/ijasr/article/view/5180>


Copyright (c) 2019 International Journal of Advances in Scientific Research. This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/)

### 1. Introduction

Irritable bowel syndromes (IBS) are a frequent painful disease that largely impacts on vigor facility throughout the world-wide, they mainly influenced through sensory functions of intestine, motility and psychosocial aspect [1], pigeonholed by abdominal pain and malformed bowel habit with uneasiness. They affect most predominant in both genders particularly before the 50 years aged group individuals, bowel syndrome endure from primitive antipathy, anxious gastrointestinal motility, and atypical gut oozing [2]. Every individual has a particular indicator depending upon their age group, effects intellectual leading depression, migraine, and anxiety, multi-factorial discomfort associated with many organs [3]. The main identification of bowel based on their subtype and patient feels some changes were present at the time of IBS-C(constipation) or IBS-D (dierrieha) to IBS-A (alternate IBS)in which IBS-C and IBS-D are more familiar[4].

### 2. Pathophysiology

In general, the bowel syndrome is the found root of complex relationship between the brain-gut axis due to the number of peripheral and central abnormalities, the patients suffer from allergy or hypersensitivity with nutrient food supplements [5]. Bowel disorders have a chain like the connection between gastrointestinal neuro-endocrine peptide/amines (NEPA) and resistant system, inflammation occurs during abnormalities in entero-endocrine cubicle and neuron [6], which acquire gastrointestinal tract interruption. The study performs that innate immune rejoinder get increased with patient activation of toll-like receptor and this activation depend on infectious gastroenteritis and psychosomatic anxiety [7]. The patients endure from disquiet, somatisation, misery, and hypochondria that seem pathogenesis allied with the impervious system, inheritance, milieu, microbiota, and quarrel of the neuroendocrine system [8].



**Figure 1: Shows pathogenesis of irritable bowel disease**

### 3. Mechanism of Bowel Disease

Bowel syndrome are most commonly related to genetic factors from parents to off-springs, certain experiment reveals that children affect from this syndrome have more complain about GI tract, the ecological contribution effects on minor genes found in monozygotic (MZ) and dizygotic (DZ) twins [9]. Protease are free in bowel disease which can directly stimulate sensory neurons and generated hypersensitivity symptoms by activation of PAR2 (protease activated receptor 2) also caused somatic and visceral hyperplasia when it's governed in colon [10].

### 4. Probiotics effects of bowel syndrome

The previous study executes that IBS subtype like constipation (C-IBS), diarrhoea (D-IBS), mixed alternate bowel disease (A-IBS) have modification with bowel habits that allied through the gastrointestinal tract by influenced functional heterogeneous disorder. Mucosal inflammation is mostly observed those patients faces complication with IBS gut microbiota which can also revel in Crohn's disease and ulcerative colitis [11]. Several probiotic factors that influenced to treat with IBS like lactobacilli, streptococcus, bifidobacteria and so on. The well-known bacteria's have several positive effects on gastrointestinal tract [12] probiotics which are useful in decreasing bacterial overgrowth and prevent an imbalance of pro and anti-inflammatory cytokines in the gut [13].

### 5. Dietary guideline

The habituated of consuming feebly diet food that can easily absorb and rapidly fermentable short-chain carbohydrates in small intestine, the fermentable oligo-dimono-saccharides and polyols (FODMAP) like toadstool, paprika, *Allium ampeloprasum*, raw *brassica oleracea*, unrefined vegetables, milk, and caffeine, are some victuals develop bowel symptoms [14], the dietician suggest that FODMAP is restricted to IBS-C, IBS-M, IBS-D [15].

### 6. Diagnosis

So far the identification of bowels haven't proved any specific investigation includes biochemical, histopathological, radiological diagnosis that shows bowels identity, even though few analysis were reported to treat bowel such as rectal bleeding, anaemia, weight loss, nocturnal symptoms, infection and inflammation [16], the evaluated lactose hydrogen breath test, thyroid function test, faecal ova or parasite determination used as primary investigation [17-18].

### 7. Treatment

Bowels can't be treated with any specific medication, but risk factors of bowels can mimic with proper exercise, hassle management along psychosomatic healing [19], constipation-IBS patient treats with bulking agents and laxatives, antispasmodics used to reduce GI tract contraction [20], increased dietary fiber for diarrhoea furnish diphenoxylate. During anti-depression and psychosomatic or behavioural changes few treatments (21), are advice to improve their health aspects and reduce distress by mindfulness treatment and therapy for 3 months [22]. Few anti-cholinergic drugs are favourable to heal bowel syndrome that avoids colonic spasm and reprieve in constipation and pain [23]. Present researcher originates that Lubiprostone is a 5-HT<sub>4</sub> agonist curve bowel syndrome, with anti-depression drugs like tricyclic, serotonin reuptake inhibitor [24].

### 8. Conclusion

Bowel syndromes are multi-factorial disorders that correlate with brain and gut axis dilemma caused disturb intestinal symptoms, visceral hypersensitivity, psychological distress, and invulnerable system, mutual probiotics are more effective to treat bowel syndrome. The pharmacopeia drugs are diver's effects on Crohn's disease and ulcerative colitis by influences mucosal inflammation, that proves bowel syndrome need to concentrate the healthy microbiota, can help to reduce bowel symptoms.

**Conflict of Interest Statement:** Author declares no conflict of interest.

**Funding:** No source of funding

**Ethics approval and consent of participate:** Not applicable.

## Reference

- [1]. Camilleri, M., & CHOI, M. G. Irritable bowel syndrome. *Alimentary pharmacology & therapeutics* 1997; 11(1): 3-15.
- [2]. El-Salhy, M., Danielsson, A., Stenling, R., & Grimelius, L. Colonic endocrine cells in inflammatory bowel disease. *Journal of internal medicine*, 1997; 242(5): 413-419.
- [3]. Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Spiller, R. C. Irritable bowel syndrome. *Nature Reviews. Disease Primers*, 2016; 2: 16014. <http://doi.org/10.1038/nrdp.2016.14>
- [4]. Lacy, B. E., Chey, W. D., & Lembo, A. J. (2015). New and Emerging Treatment Options for Irritable Bowel Syndrome. *Gastroenterology & Hepatology*, 2015; 11(4 Suppl 2): 1–19.
- [5]. Hayes, P. A., Fraher, M. H., & Quigley, E. M. M. Irritable Bowel Syndrome: The Role of Food in Pathogenesis and Management. *Gastroenterology & Hepatology*, 2014; 10(3): 164–174.
- [6]. El-Salhy, M. Irritable bowel syndrome: Diagnosis and pathogenesis. *World Journal of Gastroenterology* 2012; 18(37): 5151–5163. <http://doi.org/10.3748/wjg.v18.i37.5151>
- [7]. Saha, L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. *World Journal of Gastroenterology* 2014; 20(22): 6759–6773. <http://doi.org/10.3748/wjg.v20.i22.6759>
- [8]. El-Salhy, M., Solomon, T., Hausken, T., Gilja, O. H., & Hatlebakk, J. G. Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease. *World Journal of Gastroenterology*, 2017; 23(28): 5068–5085. <http://doi.org/10.3748/wjg.v23.i28.5068>
- [9]. Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P. & Whorwell, P. Guidelines on the irritable bowel syndrome: mechanisms and practical management. *Gut*, 2007; 56(12): 1770.
- [10]. Cenac, N., Andrews, C. N., Holzhausen, M., Chapman, K., Cottrell, G., Andrade-Gordon, P., & Sharkey, K. A. Role for protease activity in visceral pain in irritable bowel syndrome. *Journal of Clinical Investigation*, 2007; 117(3): 636.
- [11]. Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. *World Journal of Gastroenterology*, 2016; 22(7): 2219.
- [12]. Dai, C., Zheng, C. Q., Jiang, M., Ma, X. Y., & Jiang, L. J. Probiotics and irritable bowel syndrome. *World Journal of Gastroenterology*: 2013; 19(36): 5973.
- [13]. Meier, R. Probiotics in irritable bowel syndrome. *Annals of nutrition and metabolism*, 2010; 57(Suppl. 1): 12-13.
- [14]. Gaylord, S. A., Palsson, O. S., Garland, E. L., Faurot, K. R., Coble, R. S., Mann, J. D., & Whitehead, W. E. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. *The American journal of gastroenterology*, 2011; 106(9): 1678-1688.
- [15]. Rao, S. S. C., Yu, S., & Fedewa, A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. *Alimentary pharmacology & therapeutics*, 2015; 41(12): 1256-1270.
- [16]. El-Salhy, M. Irritable bowel syndrome: diagnosis and pathogenesis. *World Journal of Gastroenterology* 2012; 18(37): 5151.
- [17]. Hamm, L. R., Sorrells, S. C., Harding, J. P., Northcutt, A. R., Heath, A. T., Kapke, G. F., & Mangel, A. W. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. *The American Journal of Gastroenterology*, 1999; 94(5): 1279-1282.
- [18]. Camilleri, M., Heading, R. C., & Thompson, W. G. Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. *Alimentary Pharmacology & Therapeutics*, 2002; 16(8): 1407-1430.
- [19]. Ljótsson, B., Hedman, E., Andersson, E., Hesser, H., Lindfors, P., Hursti, T., & Andersson, G. Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial. *The American Journal of Gastroenterology*, 2001; 106(8): 1481.
- [20]. Konturek, P. C., Brzozowski, T., & Konturek, S. J. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. *J Physiol Pharmacol*, 2011; 62(6): 591-599.
- [21]. Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Muller-Lissner, S. A. Functional bowel disorders and functional abdominal pain. *Gut*, 1999; 45(suppl 2): II43-II47.
- [22]. Mazzawi, T., & El-Salhy, M. Effect of diet and individual dietary guidance on gastrointestinal endocrine cells in patients with irritable bowel syndrome. *International Journal of Molecular Medicine*, 2017; 40(4): 943-952.
- [23]. Piai, G., & Mazzacca, G. Prifinium bromide in the treatment of the irritable colon syndrome. *Gastroenterology*, 1979; 77(3): 500-502.
- [24]. Grundmann, O., & Yoon, S. L. Complementary and alternative medicines in irritable bowel syndrome: an integrative view. *World Journal of Gastroenterology*: 2014; 20(2): 346.